Methylprednisolone attenuates interferon-β induced expression of HLA-DR on monocytes
The effect of methylprednisolone on constitutive and interferon-β(IFN-β) induced HLA-DR expression on monocytes from multiple sclerosis (MS) patients was investigated. Constitutive HLA-DR expression was reduced by 50% following a single dose(500 mg) of intravenous methylprednisolone (IVMP). Stimulat...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimmunology 1996-10, Vol.70 (1), p.29-35 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | 1 |
| container_start_page | 29 |
| container_title | Journal of neuroimmunology |
| container_volume | 70 |
| creator | Crockard, A.D. Treacy, M.T. Droogan, A.G. Hawkins, S.A. |
| description | The effect of methylprednisolone on constitutive and interferon-β(IFN-β) induced HLA-DR expression on monocytes from multiple sclerosis (MS) patients was investigated. Constitutive HLA-DR expression was reduced by 50% following a single dose(500
mg) of intravenous methylprednisolone (IVMP). Stimulation with natural IFN-β, in vitro, resulted in a 20 fold increase in HLA-DR expression. Following IVMP, IFN-β inducible HLA-DR levels were reduced (non-significantly) by 20–30%. Experiments in which monocytes from normal subjects and MS patients were pre-treated in vitro with methylprednisolone prior to IFN-β stimulation revealed that induction of HLA-DR was significantly inhibited; in contrast, IFN-β induced HLA-DR expression was not down-regulated following subsequent in vitro treatment with methylprednisolone. These findings suggest that the immunomodulatory effects of IVMP could be attenuated in MS patients receiving regular IFN-β therapy. |
| doi_str_mv | 10.1016/S0165-5728(96)00100-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78436281</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572896001002</els_id><sourcerecordid>78436281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-c43975b6123a67d682d92d395ad68b5a12451cc2bdb2b3e4e10d8d7c5f30ecb13</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMoOl4eQehKdFHNpUnTlch4hRFBnXVok1OMdJIxacV5LR_EZzJzwa2bJIfz_eeQD6Fjgs8JJuLiJR085yWVp5U4w5hgnNMtNCKypLksKNlGoz9kD-3H-J4gzopqF-1KKShhdISmj9C_Lbp5AONs9J13kNV9D26oe4iZdT2EFoJ3-c93qsygwWTwlfgYrXeZb7P7yVV-_ZylYuad14uUO0Q7bd1FONrcB2h6e_M6vs8nT3cP46tJrpnAfa4LVpW8EYSyWpRGSGoqaljF6_RueE1owYnWtDENbRgUQLCRptS8ZRh0Q9gBOlnPnQf_MUDs1cxGDV1XO_BDVKUsmKByCfI1qIOPMUCr5sHO6rBQBKulTrXSqZauVCXUSqeiKXe8WTA0MzB_qY2_1L9c9yH98tNCUFFbcEmSDaB7Zbz9Z8MvjtyGGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78436281</pqid></control><display><type>article</type><title>Methylprednisolone attenuates interferon-β induced expression of HLA-DR on monocytes</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Crockard, A.D. ; Treacy, M.T. ; Droogan, A.G. ; Hawkins, S.A.</creator><creatorcontrib>Crockard, A.D. ; Treacy, M.T. ; Droogan, A.G. ; Hawkins, S.A.</creatorcontrib><description>The effect of methylprednisolone on constitutive and interferon-β(IFN-β) induced HLA-DR expression on monocytes from multiple sclerosis (MS) patients was investigated. Constitutive HLA-DR expression was reduced by 50% following a single dose(500
mg) of intravenous methylprednisolone (IVMP). Stimulation with natural IFN-β, in vitro, resulted in a 20 fold increase in HLA-DR expression. Following IVMP, IFN-β inducible HLA-DR levels were reduced (non-significantly) by 20–30%. Experiments in which monocytes from normal subjects and MS patients were pre-treated in vitro with methylprednisolone prior to IFN-β stimulation revealed that induction of HLA-DR was significantly inhibited; in contrast, IFN-β induced HLA-DR expression was not down-regulated following subsequent in vitro treatment with methylprednisolone. These findings suggest that the immunomodulatory effects of IVMP could be attenuated in MS patients receiving regular IFN-β therapy.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/S0165-5728(96)00100-2</identifier><identifier>PMID: 8862132</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Autoimmune Diseases - blood ; Autoimmune Diseases - drug therapy ; Autoimmune Diseases - immunology ; Gene Expression Regulation - drug effects ; HLA-DR ; HLA-DR Antigens - biosynthesis ; HLA-DR Antigens - genetics ; Humans ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Interferon-beta - antagonists & inhibitors ; Interferon-beta - pharmacology ; Interferon-gamma - pharmacology ; Interferon-β ; Male ; Methylprednisolone ; Methylprednisolone - pharmacology ; Methylprednisolone - therapeutic use ; Monocytes ; Monocytes - drug effects ; Monocytes - immunology ; Multiple sclerosis ; Multiple Sclerosis - blood ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - immunology ; Recombinant Proteins</subject><ispartof>Journal of neuroimmunology, 1996-10, Vol.70 (1), p.29-35</ispartof><rights>1996 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-c43975b6123a67d682d92d395ad68b5a12451cc2bdb2b3e4e10d8d7c5f30ecb13</citedby><cites>FETCH-LOGICAL-c360t-c43975b6123a67d682d92d395ad68b5a12451cc2bdb2b3e4e10d8d7c5f30ecb13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0165-5728(96)00100-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8862132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crockard, A.D.</creatorcontrib><creatorcontrib>Treacy, M.T.</creatorcontrib><creatorcontrib>Droogan, A.G.</creatorcontrib><creatorcontrib>Hawkins, S.A.</creatorcontrib><title>Methylprednisolone attenuates interferon-β induced expression of HLA-DR on monocytes</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>The effect of methylprednisolone on constitutive and interferon-β(IFN-β) induced HLA-DR expression on monocytes from multiple sclerosis (MS) patients was investigated. Constitutive HLA-DR expression was reduced by 50% following a single dose(500
mg) of intravenous methylprednisolone (IVMP). Stimulation with natural IFN-β, in vitro, resulted in a 20 fold increase in HLA-DR expression. Following IVMP, IFN-β inducible HLA-DR levels were reduced (non-significantly) by 20–30%. Experiments in which monocytes from normal subjects and MS patients were pre-treated in vitro with methylprednisolone prior to IFN-β stimulation revealed that induction of HLA-DR was significantly inhibited; in contrast, IFN-β induced HLA-DR expression was not down-regulated following subsequent in vitro treatment with methylprednisolone. These findings suggest that the immunomodulatory effects of IVMP could be attenuated in MS patients receiving regular IFN-β therapy.</description><subject>Autoimmune Diseases - blood</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Autoimmune Diseases - immunology</subject><subject>Gene Expression Regulation - drug effects</subject><subject>HLA-DR</subject><subject>HLA-DR Antigens - biosynthesis</subject><subject>HLA-DR Antigens - genetics</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Interferon-beta - antagonists & inhibitors</subject><subject>Interferon-beta - pharmacology</subject><subject>Interferon-gamma - pharmacology</subject><subject>Interferon-β</subject><subject>Male</subject><subject>Methylprednisolone</subject><subject>Methylprednisolone - pharmacology</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Monocytes</subject><subject>Monocytes - drug effects</subject><subject>Monocytes - immunology</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - blood</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - immunology</subject><subject>Recombinant Proteins</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKxDAUhoMoOl4eQehKdFHNpUnTlch4hRFBnXVok1OMdJIxacV5LR_EZzJzwa2bJIfz_eeQD6Fjgs8JJuLiJR085yWVp5U4w5hgnNMtNCKypLksKNlGoz9kD-3H-J4gzopqF-1KKShhdISmj9C_Lbp5AONs9J13kNV9D26oe4iZdT2EFoJ3-c93qsygwWTwlfgYrXeZb7P7yVV-_ZylYuad14uUO0Q7bd1FONrcB2h6e_M6vs8nT3cP46tJrpnAfa4LVpW8EYSyWpRGSGoqaljF6_RueE1owYnWtDENbRgUQLCRptS8ZRh0Q9gBOlnPnQf_MUDs1cxGDV1XO_BDVKUsmKByCfI1qIOPMUCr5sHO6rBQBKulTrXSqZauVCXUSqeiKXe8WTA0MzB_qY2_1L9c9yH98tNCUFFbcEmSDaB7Zbz9Z8MvjtyGGg</recordid><startdate>19961001</startdate><enddate>19961001</enddate><creator>Crockard, A.D.</creator><creator>Treacy, M.T.</creator><creator>Droogan, A.G.</creator><creator>Hawkins, S.A.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19961001</creationdate><title>Methylprednisolone attenuates interferon-β induced expression of HLA-DR on monocytes</title><author>Crockard, A.D. ; Treacy, M.T. ; Droogan, A.G. ; Hawkins, S.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-c43975b6123a67d682d92d395ad68b5a12451cc2bdb2b3e4e10d8d7c5f30ecb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Autoimmune Diseases - blood</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Autoimmune Diseases - immunology</topic><topic>Gene Expression Regulation - drug effects</topic><topic>HLA-DR</topic><topic>HLA-DR Antigens - biosynthesis</topic><topic>HLA-DR Antigens - genetics</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Interferon-beta - antagonists & inhibitors</topic><topic>Interferon-beta - pharmacology</topic><topic>Interferon-gamma - pharmacology</topic><topic>Interferon-β</topic><topic>Male</topic><topic>Methylprednisolone</topic><topic>Methylprednisolone - pharmacology</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Monocytes</topic><topic>Monocytes - drug effects</topic><topic>Monocytes - immunology</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - blood</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - immunology</topic><topic>Recombinant Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crockard, A.D.</creatorcontrib><creatorcontrib>Treacy, M.T.</creatorcontrib><creatorcontrib>Droogan, A.G.</creatorcontrib><creatorcontrib>Hawkins, S.A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crockard, A.D.</au><au>Treacy, M.T.</au><au>Droogan, A.G.</au><au>Hawkins, S.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methylprednisolone attenuates interferon-β induced expression of HLA-DR on monocytes</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>1996-10-01</date><risdate>1996</risdate><volume>70</volume><issue>1</issue><spage>29</spage><epage>35</epage><pages>29-35</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>The effect of methylprednisolone on constitutive and interferon-β(IFN-β) induced HLA-DR expression on monocytes from multiple sclerosis (MS) patients was investigated. Constitutive HLA-DR expression was reduced by 50% following a single dose(500
mg) of intravenous methylprednisolone (IVMP). Stimulation with natural IFN-β, in vitro, resulted in a 20 fold increase in HLA-DR expression. Following IVMP, IFN-β inducible HLA-DR levels were reduced (non-significantly) by 20–30%. Experiments in which monocytes from normal subjects and MS patients were pre-treated in vitro with methylprednisolone prior to IFN-β stimulation revealed that induction of HLA-DR was significantly inhibited; in contrast, IFN-β induced HLA-DR expression was not down-regulated following subsequent in vitro treatment with methylprednisolone. These findings suggest that the immunomodulatory effects of IVMP could be attenuated in MS patients receiving regular IFN-β therapy.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>8862132</pmid><doi>10.1016/S0165-5728(96)00100-2</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5728 |
| ispartof | Journal of neuroimmunology, 1996-10, Vol.70 (1), p.29-35 |
| issn | 0165-5728 1872-8421 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78436281 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Autoimmune Diseases - blood Autoimmune Diseases - drug therapy Autoimmune Diseases - immunology Gene Expression Regulation - drug effects HLA-DR HLA-DR Antigens - biosynthesis HLA-DR Antigens - genetics Humans Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Interferon-beta - antagonists & inhibitors Interferon-beta - pharmacology Interferon-gamma - pharmacology Interferon-β Male Methylprednisolone Methylprednisolone - pharmacology Methylprednisolone - therapeutic use Monocytes Monocytes - drug effects Monocytes - immunology Multiple sclerosis Multiple Sclerosis - blood Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Recombinant Proteins |
| title | Methylprednisolone attenuates interferon-β induced expression of HLA-DR on monocytes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T08%3A58%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methylprednisolone%20attenuates%20interferon-%CE%B2%20induced%20expression%20of%20HLA-DR%20on%20monocytes&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Crockard,%20A.D.&rft.date=1996-10-01&rft.volume=70&rft.issue=1&rft.spage=29&rft.epage=35&rft.pages=29-35&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/S0165-5728(96)00100-2&rft_dat=%3Cproquest_cross%3E78436281%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78436281&rft_id=info:pmid/8862132&rft_els_id=S0165572896001002&rfr_iscdi=true |